Pulmonary hypertension: NHLBI workshop on the primary prevention of chronic lung diseases

Annals of the American Thoracic Society

Volumn 11, Issue SUPPL. 3, 2014, Pages

  Austin, Eric D ^a   Kawut, Steven M ^b   Gladwin, Mark T ^c   Abman, Steven H ^d  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d Children's Hospital Colorado   (United States)

Author keywords

Pulmonary vascular disease; Right ventricular failure

Indexed keywords

BONE MORPHOGENETIC PROTEIN RECEPTOR 2; VASODILATOR AGENT;

AIRWAY; BONE MORPHOGENETIC PROTEIN RECEPTOR 2 GENE; CHRONIC LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONNECTIVE TISSUE DISEASE; CONTRAST ENHANCEMENT; FOLLOW UP; GENE; GENE MUTATION; GENETIC RISK; GENETIC VARIABILITY; HEART AFTERLOAD; HEART CATHETERIZATION; HEART RIGHT VENTRICLE ENDDIASTOLIC VOLUME; HEMOLYTIC ANEMIA; HERITABILITY; HIGH RISK POPULATION; HISTOLOGY; HUMAN; IDIOPATHIC DISEASE; LIVER CIRRHOSIS; LUNG ANGIOGRAPHY; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; LUNG CIRCULATION; LUNG DEVELOPMENT; LUNG DYSPLASIA; LUNG HEMODYNAMICS; LUNG PRESSURE; LUNG SCINTISCANNING; LUNG VASCULAR RESISTANCE; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PORTAL HYPERTENSION; PORTOPULMONARY HYPERTENSION; PREMATURE LABOR; PREMATURITY; PRIMARY PREVENTION; PULMONARY HYPERTENSION; SECONDARY PREVENTION; SICKLE CELL ANEMIA; SYSTEMIC SCLEROSIS; THREE DIMENSIONAL ECHOCARDIOGRAPHY; TRANSBRONCHIAL BIOPSY; CHRONIC DISEASE; HYPERTENSION, PULMONARY; LUNG DISEASES; NATIONAL HEALTH ORGANIZATION; ORGANIZATION; PROCEDURES; UNITED STATES;

CHRONIC DISEASE; CONGRESSES AS TOPIC; HUMANS; HYPERTENSION, PULMONARY; LUNG DISEASES; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (U.S.); PRIMARY PREVENTION; UNITED STATES;

EID: 84899129232     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201312-443LD     Document Type: Conference Paper

References (45)

1. Rich S, Rabinovitch M. Diagnosis and treatment of secondary (non-category 1) pulmonary hypertension. Circulation 2008;118:2190-2199.
2. Tuder RM, Abman SH, Braun T, Capron F, Stevens T, Thistlethwaite PA, Haworth SG. Development and pathology of pulmonary hypertension. J Am Coll Cardiol 2009;54:S3-S9.
3. Machado RD, Eickelberg O, Elliott CG, Geraci MW, Hanaoka M, Loyd JE, Newman JH, Phillips JA III, Soubrier F, Trembath RC, et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:S32-S42.
4. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013;62:D34-D41.
5. Larkin EK, Newman JH, Austin ED, Hemnes AR, Wheeler L, Robbins IM, West JD, Phillips JA III, Hamid R, Loyd JE. Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;186:892-896.
6. Humbert M, Khaltaev N, Bousquet J, Souza R. Pulmonary hypertension: from an orphan disease to a public health problem. Chest 2007;132:365-367. (Pubitemid 47282361)
7. Ali Z, Schmidt P, Dodd J, Jeppesen DL. Predictors of bronchopulmonary dysplasia and pulmonary hypertension in newborn children. Dan Med J 2013;60:A4688.
8. Lewandowski AJ, Bradlow WM, Augustine D, Davis EF, Francis J, Singhal A, Lucas A, Neubauer S, McCormick K, Leeson P. Right ventricular systolic dysfunction in young adults born preterm. Circulation 2013;128:713-720.
9. Robbins IM, Moore TM, Blaisdell CJ, Abman SH. Improving outcomes for pulmonary vascular disease. Am J Respir Crit Care Med 2012;185:1015-1020.
10. Peng T, Tian Y, Boogerd CJ, Lu MM, Kadzik RS, Stewart KM, Evans SM, Morrisey EE. Coordination of heart and lung co-development by a multipotent cardiopulmonary progenitor. Nature 2013;500:589-592.
11. Stern DA, Morgan WJ, Wright AL, Guerra S, Martinez FD. Poor airway function in early infancy and lung function by age 22 years: a non-selective longitudinal cohort study. Lancet 2007;370:758-764. (Pubitemid 47320800)
12. Narayanan M, Owers-Bradley J, Beardsmore CS, Mada M, Ball I, Garipov R, Panesar KS, Kuehni CE, Spycher BD, Williams SE, et al. Alveolarization continues during childhood and adolescence: new evidence from helium-3 magnetic resonance. Am J Respir Crit Care Med 2012;185:186-191.
13. Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F, Das C, Elliot CA, Johnson M, DeSoyza J, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009;179:151-157.
14. Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am 2003;29:239-254. (Pubitemid 36765119)
15. Mehari A, Gladwin MT, Tian X, Machado RF, Kato GJ. Mortality in adults with sickle cell disease and pulmonary hypertension. JAMA 2012;307:1254-1256.
16. Fonseca GH, Souza R, Salemi VM, Jardim CV, Gualandro SF. Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. Eur Respir J 2012;39:112-118.
17. Parent F, Bachir D, Inamo J, Lionnet F, Driss F, Loko G, Habibi A, Bennani S, Savale L, Adnot S, et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med 2011;365:44-53.
18. Cavalli-Sforza LL, Menozzi P, Piazza A. The history and geography of human genes. Princeton: Princeton University Press; 1994.
19. Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, Brown B, Coles WA, Nichols JS, Ernst I, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004;350:886-895. (Pubitemid 38252536)
20. Ataga KI, Moore CG, Jones S, Olajide O, Strayhorn D, Hinderliter A, Orringer EP. Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. Br J Haematol 2006;134:109-115. (Pubitemid 43830036)
21. De Castro LM, Jonassaint JC, Graham FL, Ashley-Koch A, Telen MJ. Pulmonary hypertension associated with sickle cell disease: clinical and laboratory endpoints and disease outcomes. Am J Hematol 2008;83:19-25.
22. De Castro LM, Jonassiant JC, Graham FL, Ashley-Koch A, Tellen MJ. Pulmonary hypertension in ss, sc and sb thalassemia: prevalence, associated clinical sydromes, and mortality. Blood 2004;104:462a.
23. Hadengue A, Benhayoun MK, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991;100:520-528.
24. McDonnell PJ, Toye PA, Hutchins GM. Primary pulmonary hypertension and cirrhosis: are they related? Am Rev Respir Dis 1983;127:437-441. (Pubitemid 13083742)
25. Kawut SM, Krowka MJ, Trotter JF, Roberts KE, Benza RL, Badesch DB, Taichman DB, Horn EM, Zacks S, Kaplowitz N, et al. Clinical risk factors for portopulmonary hypertension. Hepatology 2008;48:196-203. (Pubitemid 351975544)
26. Vonk-Noordegraaf A, van Wolferen SA, Marcus JT, Boonstra A, Postmus PE, Peeters JW, Peacock AJ. Noninvasive assessment and monitoring of the pulmonary circulation. Eur Respir J 2005;25:758-766. (Pubitemid 40528772)
27. Ley S, Mereles D, Risse F, Grunig E, Ley-Zaporozhan J, Tecer Z, Puderbach M, Fink C, Kauczor HU. Quantitative 3D pulmonary MR-perfusion in patients with pulmonary arterial hypertension: correlation with invasive pressure measurements. Eur J Radiol 2007;61:251-255. (Pubitemid 46096678)
28. Ohno Y, Hatabu H, Murase K, Higashino T, Nogami M, Yoshikawa T, Sugimura K. Primary pulmonary hypertension: 3D dynamic perfusion MRI for quantitative analysis of regional pulmonary perfusion. AJR Am J Roentgenol 2007;188:48-56. (Pubitemid 46012489)
29. Okajima Y, Ohno Y, Washko GR, Hatabu H. Assessment of pulmonary hypertension what CT and MRI can provide. Acad Radiol 2011;18:437-453.
30. Skrok J, Shehata ML, Mathai S, Girgis RE, Zaiman A, Mudd JO, Boyce D, Lechtzin N, Lima JA, Bluemke DA, et al. Pulmonary arterial hypertension: MR imaging-derived first-pass bolus kinetic parameters are biomarkers for pulmonary hemodynamics, cardiac function, and ventricular remodeling. Radiology 2012;263:678-687.
31. Ley S, Mereles D, Puderbach M, Gruenig E, Schock H, Eichinger M, Ley-Zaporozhan J, Fink C, Kauczor HU. Value of MR phase-contrast flow measurements for functional assessment of pulmonary arterial hypertension. Eur Radiol 2007;17:1892-1897. (Pubitemid 46909681)
32. Sanz J, Kuschnir P, Rius T, Salguero R, Sulica R, Einstein AJ, Dellegrottaglie S, Fuster V, Rajagopalan S, Poon M. Pulmonary arterial hypertension: noninvasive detection with phase-contrast MR imaging. Radiology 2007;243:70-79. (Pubitemid 46579696)
33. Estépar RSKG, Black-Shinn JL, Bowler RP, Kindlmann GL, Ross JC, Kikinis R, Han MK, Come CE, Diaz AA, Cho MH, et al. Computed tomographic measures of pulmonary vascular morphology in smokers and their clinical implications. Am J Respir Crit Care Med 2013;188:231-239.
34. Zhao L, Ashek A, Wang L, Fang W, Dabral S, Dubois O, Cupitt J, Pullamsetti SS, Cotroneo E, Jones H, et al. Heterogeneity in lung 18FDG uptake in pulmonary arterial hypertension: potential of dynamic 18FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments. Circulation 2013;128:1214-1224.
35. Fang W, Zhao L, Xiong CM, Ni XH, He ZX, He JG, Wilkins MR. Comparison of 18F-FDG uptake by right ventricular myocardium in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with congenital heart disease. Pulm Circ 2012;2:365-372.
36. Zhao L, Ashek A, Wang L, Fang W, Dabral S, Dubois O, Cupitt J, Pullamsetti SS, Cotroneo E, Jones H, et al. Heterogeneity in lung 18FDG uptake in PAH: potential of dynamic 18FDG-PET with kinetic analysis as a bridging biomarker for pulmonary remodeling targeted treatments. Circulation 2013;128:1214-1224.
37. Lundgrin EL, Park MM, Sharp J, Tang WH, Thomas JD, Asosingh K, Comhair SA, DiFilippo FP, Neumann DR, Davis L, et al. Fasting 2-deoxy-2-[18f]fluoro-D- glucose positron emission tomography to detect metabolic changes in pulmonary arterial hypertension hearts over 1 year. Ann Am Thorac Soc 2013;10:1-9.
38. Matias C, Isla LP, Vasconcelos M, Almeria C, Rodrigo JL, Serra V, Zamorano J. Speckle-tracking-derived strain and strain-rate analysis: a technique for the evaluation of early alterations in right ventricle systolic function in patients with systemic sclerosis and normal pulmonary artery pressure. J Cardiovasc Med (Hagerstown) 2009;10:129-134.
39. Bellofiore A, Chesler NC. Methods for measuring right ventricular function and hemodynamic coupling with the pulmonary vasculature. Ann Biomed Eng 2013;41:1384-1398.
40. Arena R, Guazzi M, Myers J, Grinnen D, Forman DE, Lavie CJ. Cardiopulmonary exercise testing in the assessment of pulmonary hypertension. Expert Rev Respir Med 2011;5:281-293.
41. Saggar R, Khanna D, Furst DE, Shapiro S, Maranian P, Belperio JA, Chauhan N, Clements P, Gorn A, Weigt SS, et al. Exercise-induced pulmonary hypertension associated with systemic sclerosis: four distinct entities. Arthritis Rheum 2010;62:3741-3750.
42. Kovacs G, Maier R, Aberer E, Brodmann M, Scheidl S, Troster N, Hesse C, Salmhofer W, Graninger W, Gruenig E, et al. Borderline pulmonary arterial pressure is associated with decreased exercise capacity in scleroderma. Am J Respir Crit Care Med 2009;180:881-886.
43. Kovacs G, Maier R, Aberer E, Brodmann M, Graninger W, Kqiku X, Scheidl S, Troster N, Hesse C, Rubin L, et al. Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure. Arthritis Rheum 2012;64:1257-1262.
44. Pugh ME, Buchowski MS, Robbins IM, Newman JH, Hemnes AR. Physical activity limitation as measured by accelerometry in pulmonary arterial hypertension. Chest 2012;142:1391-1398.
45. Stacher E, Graham BB, Hunt JM, Gandjeva A, Groshong SD, McLaughlin VV, Jessup M, Grizzle WE, Aldred MA, Cool CD, et al. Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;186:261-272.